Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 11, 2025, titled "Zydus receives final approval from USFDA for Jaythari (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg".
Press Release Apr 11 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has received final approval from the USFDA for Jaythari (Deflazacort) Tablets in various strengths. Deflazacort is a corticosteroid used to treat Duchenne muscular dystrophy in patients aged five and older. The tablets will be manufactured at the Doppel Farmaceutici S.r.l. facility in Italy.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 18 2025
- Press Release Mar 16 2025
- Press Release Mar 14 2025
- Press Release Mar 12 2025
- Press Release Mar 10 2025
Later from Zydus Lifesciences
- Press Release Apr 16 2025
- Press Release Apr 17 2025
- ITC Reversal Of Common ITC U/s17(2) Required In Relation To Activity Of Subscription And Redemption Of Mutual Funds
- Press Release Apr 25 2025
- Press Release Apr 26 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences